• 2026-08-25 08:37:14

Thailand has updated its operational framework for Class 2-4 medical device change notification. Revised processing timelines and fee structures have been established for both standard and expert review pathways. Medical device manufacturers and importers marketing products in Thailand must review the updated criteria, evaluation periods, and associated fees prior to submitting change requests to ensure full regulatory compliance.

• 2026-08-25 08:32:41

Singapore's Health Sciences Authority (HSA) has extended the compliance date for Phase 3 implementation of Unique Device Identification (UDI) requirements from 1 November 2026 to 31 December 2026. Class C General medical devices and in vitro diagnostic (IVD) medical devices must therefore carry UDI labelling prior to import and supply in Singapore from 1 January 2027.

• 2026-08-25 07:50:09

The Medical Device Authority (MDA) of Malaysia has announced the new Automated Re-Registration Route within the MeDC@St 2.0+ platform, effective from 13 July 2026. This initiative aims to support continuous product availability, reducing administrative workload, and improving regulatory efficiency while maintaining compliance with existing MDA requirements.

• 2026-08-25 07:35:09

The Ministry of Health Malaysia (MOH) will gradually implement a Hologram Security Label for registered medical devices to help identify genuine, registered products with the Medical Device Authority (MDA) and prevent the sale of counterfeit and unregistered devices. The official announcement is scheduled to be made during IMDEC 2026 event on 26 August 2026.

• 2026-08-25 07:11:00

As general-purpose digital devices like smartphones and wearables become increasingly integrated into health monitoring, PMDA published the review guidance for home-use Software as a Medical Device (SaMD) intended to detect signs of disease and encourage users to seek medical consultation. It outlines the scope of the guidance, product description requirements, evaluation dossier, and key considerations for clinical study design, including clinical intention, design concept, clinical performance evaluation, and risk management. The summary is intended to provide an overview of the regulatory expectations for the development and evaluation of this type of SaMD and to facilitate understanding of the PMDA review approach.

• 2026-08-25 04:50:05

Indonesia's medical device regulatory framework places increasing emphasis on demonstrating compliance with applicable healthcare standards through appropriate testing and validation. Manufacturers and applicants should ensure that the required test results, validation documents, and supporting certifications are available as part of the product registration and compliance process. Recent requirements highlighted for in vitro diagnostic products (IVDs) include specific provisions for performance testing, instrument connectivity, and software validation.

• 2026-08-25 04:38:17

The Hong Kong Department of Health (DH), through its Medical Device Division (MDD), has established the "Novo Lane" under the Medical Device Administrative Control System (MDACS) to prioritize the processing of eligible innovative medical device listing applications. The initiative is intended to facilitate earlier access to innovative medical technologies while maintaining regulatory oversight of medical device safety and performance. As part of its regulatory approach, the MDD continues to monitor the safety and performance of listed medical devices after they are placed on the market.

• 2026-08-25 04:12:25

Hong Kong's Medical Device Division (MDD) has revised the Guidance Notes for Changes of Listed Medical Devices (GN-10), effective 26 June 2026. The update introduces new non-reportable change categories, revised major change criteria, conditional approval outcomes, and additional compliance requirements. Manufacturers and LRPs should review the revised requirements to ensure compliance under MDACS.

• 2026-08-25 03:20:19

Australian Institute of Health and Welfare (AIHW) recorded 323,497 elective lens-intervention admissions in 2024-25, with private hospitals accounting for 71.9% of recorded activity. With 98% of cataract surgeries delivered as same-day procedures and US$121.9M of ophthalmic instrument imports in 2025, the market combines substantial procedure activity with an established international supply channel. For global manufacturers, successful entry requires product-specific ARTG, sponsorship and UDI planning.

• 2026-07-28 03:07:42

Japan is advancing its surgical robotics sector, driven by an aging population and healthcare workforce shortages. Robotic-assisted surgery is expanding across urology, general surgery, and orthopedics, supported by growing public insurance coverage and rising institutional investment. Backed by a fast-growing market, Japan presents strategic opportunities for global medical device companies targeting the Asia-Pacific region.